HC Wainwright Issues Positive Estimate for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Stock analysts at HC Wainwright boosted their Q1 2025 earnings estimates for Allogene Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.27) for the quarter, up from their previous estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.14) EPS.

A number of other brokerages have also commented on ALLO. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research note on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.29.

Allogene Therapeutics Stock Performance

Shares of Allogene Therapeutics stock opened at $1.62 on Friday. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.63. The stock has a market capitalization of $351.97 million, a price-to-earnings ratio of -1.04 and a beta of 1.02. The company’s 50 day moving average price is $1.89 and its 200-day moving average price is $2.28.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06.

Insider Transactions at Allogene Therapeutics

In other news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the transaction, the chief executive officer now owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. The trade was a 0.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of Allogene Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the transaction, the insider now directly owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. This represents a 5.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,866 shares of company stock valued at $194,461 in the last quarter. 24.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Allogene Therapeutics

Several large investors have recently modified their holdings of ALLO. Cibc World Markets Corp purchased a new position in shares of Allogene Therapeutics in the 4th quarter worth about $26,000. PAX Financial Group LLC bought a new stake in Allogene Therapeutics in the 4th quarter worth about $27,000. RPO LLC bought a new stake in Allogene Therapeutics in the 4th quarter worth about $31,000. Caption Management LLC bought a new stake in Allogene Therapeutics in the 4th quarter worth about $32,000. Finally, Syon Capital LLC bought a new stake in Allogene Therapeutics in the 4th quarter worth about $39,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).